EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non‐Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial
In conclusion, this subgroup analysis by race (Asians and Non-Asians) supports comparable efficacy and safety between SB12 and reference eculizumab in global PNH patients including no difference in transfusion avoidance effect.
Authors
- Ji‐Hye Park (ORCID: https://orcid.org/0000-0002-6699-5202)
- Hanna Oliynyk
- Jun Ho Jang (ORCID: https://orcid.org/0000-0001-7423-4676)
- Theerin Lanamtieng (ORCID: https://orcid.org/0000-0001-6690-3024)
- Régis Peffault de Latour (ORCID: https://orcid.org/0000-0001-6222-4753)
- Ciprian Tomuleasa (ORCID: https://orcid.org/0000-0001-5500-1519)
- Paola Russo (ORCID: https://orcid.org/0000-0002-4362-4388)
- Younsoo Kim (ORCID: https://orcid.org/0000-0002-0292-1538)
- Soo Min Lim
- Jin Ah Jung (ORCID: https://orcid.org/0000-0003-2439-377X)
Institutions
- Khon Kaen University (TH)
- Université Paris Cité (FR)
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Samsung (South Korea) (KR)
- Sultanah Aminah Hospital (MY)
- Samsung Medical Center (KR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institute of Oncology Prof. Dr. Ion Chiricuta (RO)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- eJHaem
- Published
- 2025-03-21
- DOI
- https://doi.org/10.1002/jha2.70020
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00